DMT: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Tier 2 taxonomy consolidation: merge Classic Psychedelics into Classical Psychedelics (Serotonergic) |
MDElliottMD (talk | contribs) Append Erowid dose-magnitude paragraph to Pharmacodynamics (erowid-claude handoff, vetted) |
||
| Line 72: | Line 72: | ||
DMT is a substituted tryptamine whose effects in the central nervous system are mediated primarily by partial agonism at the serotonin 5-HT2A receptor, with additional activity at other 5-HT receptor subtypes and, at higher concentrations, at sigma-1 and trace amine-associated receptors.<ref name="nichols2016">Nichols DE. Psychedelics. Pharmacological Reviews. 2016;68(2):264-355. PMID: 26841800.</ref> Taken orally without an accompanying inhibitor, DMT is inactive: monoamine oxidase A in the gut and liver metabolizes it before it reaches the brain. Inhalation, insufflation, or parenteral administration bypass this first-pass destruction, as does oral co-administration with a monoamine oxidase inhibitor, which is the pharmacological logic of ayahuasca. Plasma elimination half-life after intravenous administration is approximately 9 to 12 minutes, among the shortest of any psychoactive medicine in clinical use. | DMT is a substituted tryptamine whose effects in the central nervous system are mediated primarily by partial agonism at the serotonin 5-HT2A receptor, with additional activity at other 5-HT receptor subtypes and, at higher concentrations, at sigma-1 and trace amine-associated receptors.<ref name="nichols2016">Nichols DE. Psychedelics. Pharmacological Reviews. 2016;68(2):264-355. PMID: 26841800.</ref> Taken orally without an accompanying inhibitor, DMT is inactive: monoamine oxidase A in the gut and liver metabolizes it before it reaches the brain. Inhalation, insufflation, or parenteral administration bypass this first-pass destruction, as does oral co-administration with a monoamine oxidase inhibitor, which is the pharmacological logic of ayahuasca. Plasma elimination half-life after intravenous administration is approximately 9 to 12 minutes, among the shortest of any psychoactive medicine in clinical use. | ||
Doses used outside the research setting are not standardized. Harm-reduction documentation such as the Erowid DMT Vault records inhaled use ranging from a few milligrams to roughly sixty milligrams, with effects beginning within about a minute and largely resolving within twenty minutes.<ref name="erowid-dmt-dose">Erowid. DMT Dosage. Erowid DMT Vault, 1997, last modified 21 February 2015. https://www.erowid.org/chemicals/dmt/dmt_dose.shtml (accessed 21 May 2026).</ref> Because DMT is active in the range of tens of milligrams and the purity of any non-pharmaceutical preparation is uncertain, the dose actually received outside a clinical setting is difficult to know, a point of practical relevance when a clinician is assessing a patient's reported exposure. | |||
| interactions = <pharmaInteractions/> | | interactions = <pharmaInteractions/> | ||
| seealso = [[Ayahuasca]], [[LSD]] | | seealso = [[Ayahuasca]], [[LSD]] | ||